ESC 2025: β-blockers after myocardial infarction with mildly reduced ejection fraction
05/1/2026 | 4min
📚 ESC 2025 Coverage: Expanding the Benefit Zone: Can β Blockers Help Post-MI Patients with Mildly Reduced Ejection Fraction? by Dr. Yahyavi, Cardiovascular Researcher.
ESC 2025: SMuRF-less but inflamed
04/1/2026 | 4min
📚 ESC 2025 Coverage: The SMuRF-less Illusion: Inflammation Unmasks Hidden Cardiovascular Risk in Healthy Women, by Dr. Hafezi, Cardiovascular Specialist.
ESC 2025: Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction
03/1/2026 | 6min
📚 ESC 2025 Coverage: A Classic Revived: Digitoxin Lowers Risk in HFrEF When Added to Modern Therapy, by Dr. Talasaz, Clinical Pharmacist.
ESC 2025: Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy
03/1/2026 | 6min
Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy
ESC 2025: Immediate versus staged complete revascularisation during index admission in patients
02/1/2026 | 13min
📚 ESC 2025 Coverage: All at Once or One Step at a Time? Immediate Revascularisation Falls Short of Non-Inferiority in STEMI Patients, by Dr. Soltani Moghadam, Cardiovascular Researcher.